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Background—Individuals at clinical high-risk (CHR) who progress to fully psychotic symptoms 
have been observed to show a steeper rate of cortical gray matter reduction compared with those 
without symptomatic progression and with healthy controls. Whether such changes reflect 
processes associated with the pathophysiology of schizophrenia or exposure to antipsychotic drugs 
is unknown.
Methods—In this multisite study, 274 CHR cases, including 35 who converted to psychosis, and 
135 healthy comparison subjects were scanned with MRI at baseline, 12-month follow-up, and/or 
the point of conversion for those who developed fully psychotic symptoms.
Results—In a traveling subjects sub-study, we observed excellent reliability for measures of 
cortical thickness and subcortical volumes. Controlling for multiple comparisons throughout the 
brain, CHR converters showed a steeper rate of gray matter loss in right superior frontal, middle 
frontal, and medial orbitofrontal cortical regions, as well as a greater rate of expansion of the third 
ventricle, compared with CHR non-converters and healthy controls. Differential tissue loss was 
present among cases who had not received antipsychotic medications during the inter-scan interval 
and was predicted by baseline levels of an aggregate measure of pro-inflammatory cytokines in 
plasma.
Conclusions—These findings demonstrate that the brain changes are not explained by exposure 
to antipsychotic drugs, but likely play a role in psychosis pathophysiology. Given that the cortical 
changes were more pronounced among cases with briefer durations of prodromal symptoms, 
contributing factors may predominantly play a role in acute-onset forms of psychosis.
Keywords
schizophrenia; psychosis; prodromal; MRI; prefrontal cortex; inflammation
Evidence of progressive loss of gray matter among clinical high-risk (CHR) individuals who 
convert to psychosis (1–7) suggests that disturbances in neuromaturational processes during 
the transition from adolescence to early adulthood (8–12) may play a role in psychosis onset. 
However, a number of questions remain to be answered before such an interpretation would 
be warranted.
First, this effect may be a secondary phenomenon. Antipsychotic drugs are associated with 
gray matter decline in animal models (13) and in patients with schizophrenia (14, 15), 
including first-episode patients (16). Because the follow-up scans for converting CHR cases 
in all longitudinal MRI studies occurred post-conversion, most of the converters (and 
relatively fewer of the non-converters) received antipsychotic drug treatment during the 
inter-scan interval. In the only prior study to examine this question, converters who had not 
received antipsychotics during the inter-scan interval (n=5) did not differ in rate of tissue 
loss from converters who did receive antipsychotics prior to the follow-up scan (n=5) (5). 
However, this comparison was almost certainly underpowered to detect a difference if one 
exists; in any case, a more conclusive result would emerge from comparing the rate of loss 
among converters not exposed to antipsychotics during the inter-scan interval with non-
converters and controls.
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If the accelerated gray matter loss associated with psychosis onset is not a secondary 
phenomenon, then it could be related to factors that participate in the pathophysiology of 
schizophrenia and related disorders, such as neuroinflammation (17). Neuroinflammatory 
markers are elevated in postmortem neural tissue from patients with schizophrenia (18), and 
these same markers are associated with microglial-mediated synaptic pruning and dendritic 
retraction in animal models (19), thus providing a potential mechanistic basis for the 
reduced neuropil seen in patients (20). Although neuroinflammatory processes initiated 
during prenatal stress exposures could play a role (21), activation of such processes in 
association with the synaptic pruning characteristic of adolescent brain development 
represents an influence more proximal to psychosis onset (12, 17, 20, 21). Recently, an 
elevation in plasma-based markers of inflammation and oxidative stress was found to 
precede and predict onset of psychosis among CHR cases (22). It remains to be determined 
whether such markers also predict the acceleration in gray matter loss around the time of 
psychosis onset.
Given that CHR cases are ascertained at different ages and at various points along the 
putative trajectory toward overt illness, such variability could obscure different subgroups of 
future converters with different profiles of change in brain structure over time. In particular, 
accelerated gray matter decline would be expected especially among cases with shorter 
durations from onset of prodromal symptoms to conversion (because the underlying 
pathology among cases with longer durations would likely be relatively more slowly 
progressing). In addition, although studies of early psychosis patients are generally 
consistent in showing lower volumes in dorsolateral prefrontal, superior temporal, and 
parahippocampal cortex (23, 24), prior longitudinal MRI studies are in conflict as to whether 
the steeper rate of loss in CHR converters is general or specific to these regions (1–7). 
However, these discrepancies may merely reflect regional differences in measurement 
reliability and/or between-study differences in statistical power.
In this multisite study, 274 CHR cases, including 35 who converted to psychosis, and 135 
demographically comparable healthy comparison subjects were scanned with MRI at 
baseline and at 12-month follow-up and/or the point of conversion for those who developed 
fully psychotic symptoms (25). We hypothesized that converters would show steeper rates 
of gray matter reduction in prefrontal, superior temporal, and parahippocampal regions 
compared with non-converters and controls and that these effects would be present among 
cases without exposure to antipsychotic medications during the inter-scan interval. We 
further hypothesized that the cortical changes would be greatest among cases with a more 
recent onset of prodromal symptoms and that baseline levels of pro-inflammatory cytokines 
would predict the rate of gray matter loss especially among converters. We also evaluated 
statistical power to detect differential change across brain regions by incorporating 
information on reliability from a traveling subjects substudy.
Methods
Subjects
The study protocol and consent form was reviewed and approved by the Institutional 
Review Boards at each of the 8 data collection sites (UCLA, Emory, Beth Israel Deaconess 
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Medical Center, Zucker Hillside Hospital, UNC, UCSD, Calgary, Yale). Participants were 
evaluated using the Structured Interview for Prodromal Syndromes (SIPS) (26) and the 
Structured Clinical Interview for Axis I Diagnostic and Statistical Manual of Mental 
Disorders, Version IV (DSM-IV) (27) at each assessment by trained interviewers who met 
high reliability standards (ICCs=0.92–0.96) (25). CHR cases met SIPS/SOPS criteria for a 
psychosis risk syndrome,(26) excluding cases who had ever met DSM-IV criteria for a 
psychotic disorder. Control participants were excluded if they met criteria for a psychotic 
disorder, had a first-degree relative with a current or past psychotic disorder, or met 
prodromal criteria. General exclusions included substance dependence, neurological 
disorder, or full scale IQ < 70.
Subjects included in this report are those with MRI scans at baseline (BL) and at 12-month 
follow-up (FU) or at the point of conversion to psychosis. Given that nearly all (37/41) of 
the converters with both BL and FU scans available had converted before the scheduled 12-
month FU, few converting subjects had FU scans prior to conversion. To avoid mixing cases 
whose FU scans occurred pre and post-conversion, the 4 converters whose FU scans were 
obtained prior to conversion were excluded from the primary analyses (but included in 
secondary analysis). In total, 35 CHR cases who converted to psychosis, 239 CHR cases 
who did not convert, and 135 healthy comparison subjects had usable data and were 
included. These subjects were drawn from the larger pools of subjects (N’s=62 converters, 
491 non-converters, and 224 controls) who had been scanned at baseline. Subjects with both 
BL and FU scans available did not differ from subjects with BL scans only on age, sex, 
education, parental education or socioeconomic class overall or in any group separately (all 
p-values > .30).1 Demographic characteristics of the three groups are shown in Table 1. 
There were no significant differences in age, sex, site of origin, or socioeconomic class by 
group. Non-converters had lower parental education than converters and controls, who did 
not differ. Converters and non-converters had a higher rate of substance use disorders than 
the controls but did not differ from each other. The inter-scan interval was significantly 
briefer among converters compared to non-converters and controls, who did not differ. 
Dividing at the median duration from onset of prodromal symptoms to FU scan among 
converters (26 months, range=2 to 149 months) produced subgroups of 18 cases with short 
durations and 17 with long durations. For non-converters, applying the same cutoff resulted 
in 140 cases with short durations and 76 with long durations (information on age at onset of 
symptoms was not available for the remaining 23 non-converters).
As this was a naturalistic study, subjects were treated in their respective communities 
according to prevailing standards and the judgment of the treating clinicians, who were often 
primary care physicians rather than psychiatrists. We collected and coded information on 
medication prescriptions at baseline, 6- and 12-month follow-up (and at the conversion 
assessment when relevant). Based on this information, 13 (37%) of the 35 converters and 
166 (70%) non-converters had not received antipsychotics during the inter-scan interval.
1Subjects who were not scanned had a slightly lower level of education (11.1 vs 11.9 years) and greater proportion of females (49% vs 
42%) compared with those who were scanned, but did not differ on other demographic characteristics.
Cannon et al. Page 4
Biol Psychiatry. Author manuscript; available in PMC 2016 January 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
MRI Scans
Five sites operated Siemens scanners and three sites operated GE scanners, all at 3 Tesla. All 
Siemens sites used a 12-channel head coil and all GE sites used an 8-channel head coil. 
Sequence parameters were optimized for each scanner manufacturer, software version and 
coil configuration according to the ADNI protocol (http://adni.loni.ucla.edu/research/
protocols/mri-protocols/). Scans were acquired in the sagittal plane with a 1mm × 1mm in-
plane resolution and 1.2mm slice thickness. Siemens scanners used an MPRAGE sequence 
with a 256 (axial) × 240 (sagittal) × 176 (coronal) mm field of view, TR/TE/
TI=2300/2.91/900ms and a 9 degree flip angle, while GE scanners used an IR-SPGR 
sequence (efgre3d_cs) with a 26cm field of view, TR/TE/TI=7.0/minimum full/400ms and 
an 8 degree flip angle.
Image Processing, Quality Assurance, and Reliability
All MR images were processed using Freesurfer v5.2 (http://surfer.nmr.mgh.harvard.edu/) at 
Yale by investigators who had participated in the Freesurfer training course. Surface-based 
cortical reconstruction was performed to extract thickness measures by calculating the 
shortest distance from each point on the gray/white boundary to the pial surface at each 
vertex, along with subcortical volumetric segmentation (28–32). The subcortical 
segmentation procedure assigns a neuroanatomical label to each voxel of the MRI volume 
using a probabilistic atlas and a Bayesian classification rule (30). The reconstructed baseline 
and follow-up scans were further processed using Freesurfer’s longitudinal stream to extract 
change in thickness and volume estimates (33). This processing stream initializes each time 
point scan by utilizing an unbiased within-subject template space and average image (34), 
created by robust, inverse consistent registration (35), which has been shown to significantly 
increase statistical power for detecting subtle changes over time (33). The Supplementary 
Material provides details of the quality assurance procedures.
Each of the 8 sites also recruited one healthy subject (4 males, 4 females) who was scanned 
twice on successive days at every site to permit evaluation of between-site and test-retest 
reliabilities using intraclass correlations (ICCs). In addition, the ADNI structural phantom 
was scanned at each site and processed using the AQUAL2 algorithm (36). We have 
previously reported on phantom-based performance metrics as well as two processing 
streams applied to the traveling human data: cortical pattern matching and voxel-based 
morphometry (37). Briefly, the 8 scanners performed within the range of accepted tolerance 
according to the phantom-based metrics, and all achieved excellent reliabilities for 
intracranial, brain, gray matter, white matter, and subcortical volumes. Superior reliability 
was achieved when using surface-based registration (as implemented in Cortical Pattern 
Matching) compared with standard VBM registration and when applying a global scaling 
correction. Because Freesurfer incorporates both surface-based registration and global 
scaling correction but also has a built-in module for voxel-based correction of the Type I 
error rate (which Cortical Pattern Matching does not), we opted to process the imaging data 
from the primary study using Freesurfer, and in the Supplementary Material we report the 
test-retest ICCs for Freesurfer-derived measures of cortical thickness and subcortical and 
ventricular volumes from the traveling subject substudy.
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Blood Analytes
As part of a pilot study, blood samples obtained at the BL assessment for 87 of the subjects 
with BL and FU MRI scans available (14 converters, 38 non-converters, 35 controls) were 
processed using the Luminex® Human DiscoveryMap® bead-based multiplex immunoassay. 
Blood samples were collected in Becton Dickenson P100 tubes containing EDTA and 
proprietary protein stabilizers along with a mechanical separator and stored at −80°C until 
analysis. Analytes were transformed to z-scores based on the means and standard deviations 
of the control group. Although particular cytokines may have differential functions (e.g., 
pro- vs anti-inflammatory) in different contexts, several included in the Luminex panel (i.e., 
TNF-α, IL-2, Interferon-γ) are consistent activators of the M1 cytotoxic phenotype of 
microglia (38–41); these were summed together into an index of pro-inflammatory 
signaling. Similarly, four analytes most consistently associated with the M2 repair and 
regeneration phenotype of microglia (i.e., IL-10, GM-CSF, IL-1RN, Chemokine [C-C motif] 
ligand 2) (38–41) were summed together to form an index of anti-inflammatory signaling.
Statistical Analysis
Imaging measures were first transformed to annualized rates of change (ARCH) in each 
cortical voxel and each subcortical and ventricular region of interest (ROI), where ROIARCH 
= ((ROIFU − ROIBL)/ROIBL)/Interval and where Interval is the time between BL and FU 
scans in years. This approach was preferred to repeated-measures ANOVA because the 
inter-scan interval varied across subjects (but results that were significant based on 
annualized rate of change were also significant using repeated measures ANOVA). Primary 
hypothesis testing was applied to measures of cortical thickness in Freesurfer using the 
False-Discovery Rate (FDR) correction for multiple comparisons at the voxel level. In 
addition, volumetric measures of the ventricular system and subcortical nuclei were 
evaluated in separate analyses of variance (ANOVAs), treating hemisphere as a repeated 
measure where appropriate, and controlling for multiple comparisons by FDR correction. 
Models included age at BL, gender, site, and group (Converter, Non-Converter, and Control) 
as predictors.
Secondary analyses were conducted to determine the contributions of antipsychotic drug 
exposure, duration of prodromal symptoms, and the plasma indices of pro- and anti-
inflammatory cytokines to the regional measures showing evidence of differential change 
over time by group status. In one set of ANOVAs, converters with and without antipsychotic 
drug exposure during the inter-scan interval were compared with non-converters with and 
without antipsychotic use and controls. In another set of ANOVAs, converters with short 
durations of prodromal symptoms with compared to those with longer durations, non-
converters with short and long durations, and controls. A third set of analyses evaluated the 
linear regressions of change in cortical thickness measures on BL levels of pro- and anti-
inflammatory cytokines.
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Results
Baseline Differences
There were no significant differences between converters, non-converters and controls in 
terms of cortical thickness or subcortical or ventricular volumes at BL, nor did BL measures 
vary by duration of prodrome among converters.
Rates of Change
Figure 1 shows statistical brain atlases plotting differences in the mean annualized rates of 
change in cortical thickness among converting CHR subjects, non-converting CHR subjects, 
and healthy controls. In the uncorrected maps (upper panels), converters showed steeper 
rates of reduction in cortical thickness in a large cluster including the left and right superior 
frontal, middle frontal, and medial orbitofrontal gyri compared with both controls and non-
converters, and in smaller clusters in the right superior and inferior parietal cortex, superior 
temporal gyrus and parahippocampal gyrus, compared with controls. After applying an FDR 
correction thresholded at p≤0.01 (two-tailed), only the differences in right superior frontal, 
middle frontal, and medial orbitofrontal regions remained significant for both contrasts 
(Figure 1, lower panels). There were no significant differences in rates of change between 
non-converting CHR subjects and controls before or after FDR correction. In parallel 
analyses of the volumes of subcortical and ventricular ROIs (Table 1), converters showed 
significantly greater expansion of the third ventricle compared with non-converters and 
controls, who did not differ from each other.
Given that the reliabilities of thickness measures from most regions of cortex and most 
subcortical volumes were equivalent to or higher than that in right superior frontal and 
medial orbitofrontal cortex (ICCs=0.92 and 0.68, respectively; see Supplementary Material), 
the topography of regions showing differential change over time in converters must 
primarily reflect differences in the true effect sizes rather than measurement reliability. The 
effect size observed in right superior frontal and medial orbitofrontal gyrus was quite large 
(d=−1.0). In fact, there were medium to large effect sizes (d=−0.30 to −0.63) across most of 
the remaining bilateral prefrontal cortex (including middle and inferior frontal gyri and 
frontal pole) and bilateral parahippocampal gyrus.
A mask applied to the FDR-corrected p-maps was used to isolate the prefrontal regions 
showing significantly greater thinning in converters compared with non-converters and 
controls; the annualized rates of change for this measure and third ventricle volume were 
carried forward for use in subsequent analyses.
Antipsychotic Medications and Timing of Follow-Up Scan
Converters without any anti-psychotic drug exposure during the inter-scan interval showed 
significantly greater reduction in right prefrontal cortex thickness and significantly greater 
expansion of the third ventricle compared with non-converters with and without such 
exposure and with healthy controls, but did not differ from converters with anti-psychotic 
drug exposures on these measures (Figure 2). On average, the follow-up scan for converters 
occurred 141 days (SD = 117 days) after conversion. Neither this interval, nor the duration 
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or dosage of antipsychotic medications during the inter-scan interval, was significantly 
correlated with the rate of prefrontal cortical thinning or third ventricle expansion (Table 2).
Duration of Prodrome
CHR cases with a shorter duration of prodromal symptoms showed a significantly steeper 
reduction in right prefrontal thickness compared with long-duration converters, short- and 
long-duration non-converters, and controls; they also showed significantly greater third 
ventricle expansion compared with all of the other groups except for long-duration 
converters (Figure 3). Long-duration converters showed a steeper rate of prefrontal thinning 
and third ventricular expansion compared with long-duration non-converters and controls, 
but did not differ from short-duration non-converters on these measures.
Markers of Inflammation
Although the three groups did not differ significantly from each other in mean levels of pro-
inflammatory (F=0.95, p=0.39) or anti-inflammatory (F=0.98, p=0.38) cytokines at BL, the 
rate of prefrontal cortical thinning was significantly associated with higher levels of pro-
inflammatory markers in the sample overall, and this inverse correlation was significantly 
greater among converters than among non-converters and controls (Table 3). Pro-
inflammatory cytokines were not associated with third ventricular expansion, and anti-
inflammatory cytokines were not associated with rate of change in either of the MRI 
measures.
Discussion
Individuals at clinical risk who develop psychosis show a steeper rate of gray matter loss in 
right superior frontal, middle frontal, and medial orbitofrontal cortex, as well as a greater 
rate of expansion of the third ventricle, compared with at risk individuals who do not 
convert and healthy comparison subjects. Importantly, these effects were present among 
cases who had not received antipsychotic medications during the inter-scan interval, 
demonstrating that the differential tissue loss associated with onset of psychosis is not 
explained by exposure to antipsychotic drugs. This finding represents a critical advance, 
given that antipsychotics clearly complicate the interpretation of progressive brain changes 
among patients in the first-episode of psychosis (13–16). A similar result was observed 
among unmedicated familial high-risk subjects who showed increasing symptom severity 
(42). It is thus possible that progressive gray matter reduction is in some way linked to the 
pathophysiology of onset of psychosis.
Prior studies of CHR cases have reported steeper reductions in prefrontal, superior temporal, 
and parahippocampal regions among converters compared with non-converters (1–7). The 
sample sizes in those studies were significantly smaller than in the present one, and none 
employed a voxel-based correction for multiple comparisons. Because the traveling subjects 
substudy revealed comparably high test-retest reliability across most cortical and subcortical 
regions, the topographical pattern of differential change in this study primarily reflects 
regional variation in effect size, which was sufficiently high in right superior and medial 
prefrontal regions and in the third ventricle to survive rigorous control for multiple 
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comparisons throughout the brain. This study thus strongly confirms prior evidence of 
differential tissue loss in prefrontal cortex among CHR converters to psychosis, with a 
topography highly similar to that in the only prior study using surface-based anatomical 
comparison (2). The primary advantage of the voxel-based FDR-corrected threshold 
employed here is that it protects against false positive findings given the number of tests 
conducted and distribution of observed p-values. Thus, we can have high confidence that the 
effects that were significant are true positives. Adoption of this conservative threshold might 
also lead to some false negative results. In fact, there were medium to large effect sizes 
across most of the remaining bilateral prefrontal cortex (including left and right middle and 
inferior frontal gyri and frontal pole) and bilateral parahippocampal gyrus, as well as in 
some circumscribed regions of temporal and parietal cortex, overlapping the regions 
showing differential change in prior studies (1–7).
Higher levels of a plasma-based aggregate index of pro-inflammatory cytokines at baseline 
were strongly predictive of steeper rates of gray matter reduction in right prefrontal cortex 
among CHR cases who converted to psychosis. Given that peripheral cytokines can affect 
brain function (43), and because the cytokines included in the pro-inflammatory index are 
potent activators of the M1 cytotoxic phenotype of microglia that result in synaptic pruning 
and dendritic retraction (38–41), it is plausible to hypothesize a mechanistic link between 
neuroinflammation (i.e., microglial activation) and progressive gray matter loss in 
individuals who develop psychosis, a hypothesis that should be tested using more direct 
indicators of neuroinflammatory processes in CHR subjects.
The steeper rate of decline in right prefrontal cortex and expansion of the third ventricle 
were more pronounced among converters with shorter durations than those with longer 
durations, but the long-duration converters also showed differential change compared with 
non-converters and controls. This pattern suggests that a steeper rate of tissue loss in these 
regions, or the factors promoting it, may help to trigger an earlier onset of psychosis. 
Because there were no significant differences between converters, non-converters and 
controls in cortical thickness or subcortical volumes at the BL assessment controlling for 
multiple comparisons, this finding suggests that the reductions in gray matter emerge around 
the time of onset of psychosis, rather than earlier, among CHR cases. Some but not all prior 
studies have detected anatomical differences at baseline between CHR individuals who do 
and do not later convert, despite the use of much smaller sample sizes than that in this study, 
by focusing on a small number of regions of interest or by otherwise employing a less 
conservative statistical threshold (1, 3, 4, 44–62). Nevertheless, it must be kept in mind that 
the CHR criteria are sensitive primarily to acute onset forms of psychosis and may therefore 
underrepresent cases with more insidious onsets, who might manifest loss of gray matter 
volume at earlier assessment points due to early life risk exposures, such as fetal hypoxia 
(63). Thus, the extent to which future converters manifest anatomical deficits at baseline 
could also potentially reflect the relative proportions of converters with insidious vs. acute 
onsets in the sample under study.
The question arises as to whether gray matter reduction per se is a causal factor in onset of 
psychosis. Given that the distributions of cortical gray matter volumes among patients with 
schizophrenia and healthy controls overlap by 50–75%, it does not appear that there is a 
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critical threshold of cortical thickness (in any one region or combination of regions) below 
which psychosis develops. Nevertheless, there is likely to be a threshold of integrated 
synaptic activity and regional functional connectivity that does discriminate those in a 
psychotic state from others. Gray matter reduction is perhaps best conceptualized as a 
marker of a set of processes that contributes to reductions in integrated synaptic activity and 
functional connectivity, which in turn might represent a proximal sufficient mechanism of 
psychosis onset. Although there are likely mechanisms that disrupt synaptic activity and 
functional connectivity in psychosis-relevant networks without affecting cortical volume, 
gray matter reduction is nevertheless an observable and reliably measured phenomenon that 
appears to play a role in a significant proportion of cases and thereby provides insight into 
the network of brain regions likely to participate in psychosis onset in general.
It is important to note that in this study, as well as in all prior longitudinal studies of CHR 
cases (1–7), the follow-up scans for converters occurred after the point of conversion. 
Although the change in gray matter volume was not correlated with the interval between 
onset of psychosis and the second scan, it is not yet known whether significant change 
occurs prior to onset of psychosis. It is, however, reassuring that the absolute magnitude of 
change in the right prefrontal ROI among the four converters who had FU scans before the 
point of conversion (i.e., mean±SD=−0.11±0.08mm) was comparable to that among cases 
whose FU scans occurred post-conversion (−0.12±0.11mm) and was greater in magnitude 
compared with non-converters (−0.05±0.13mm) and controls (−0.05±0.10mm). When these 
four cases were included with those who had FU scans post-conversion, converters 
continued to show significantly greater contraction of right prefrontal cortex 
(F[2,401]=12.66, p=0.000004) compared with non-converters and controls. Given that in 
this study and in a prior large study of prodromal youth at these same sites (64), more than 
70% of the conversions had occurred by 10-months, future studies are encouraged to time 
MRI assessments at 2-month intervals from the baseline to ensure at least 2 assessment 
points prior to conversion for the majority of cases.
In conclusion, CHR cases who convert to psychosis show a steeper rate of thinning in 
prefrontal cortex, an effect that is independent of exposure to antipsychotic drugs and is 
predicted by plasma analytes indicative of an inflammatory process. Future work is 
encouraged to confirm a neuroinflammatory signature in the regions showing gray matter 
loss and to determine whether inflammation precedes and predicts the gray matter loss or is 
a consequence of it.
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Figure 1. 
Statistical brain atlases plotting differences in the mean annualized rates of change in 
cortical thickness among converting CHR subjects (n=35), non-converting CHR subjects 
(n=239), and healthy controls (n=135). Panels on the left show differences between 
converters and controls and panels on the right show differences between converters and 
non-converters. In the uncorrected maps (upper panels), compared with both non-converters 
and controls, converters showed greater thinning (warmer colors) in left and right superior 
frontal, middle frontal, and medial orbitofrontal gyri and in the right superior and inferior 
parietal cortex, superior temporal gyrus and parahippocampal gyrus. After applying an FDR 
correction (p ≤ 0.01; lower panels), only the differences in right superior frontal, middle 
frontal, and medial orbitofrontal regions remained significant for both contrasts. The small 
clusters showing greater expansion (cooler colors) in the converters compared with controls 
in the uncorrected maps did not survive correction for multiple comparisons. There were no 
differences between non-converters and controls before or after FDR correction.
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Figure 2. 
Mean annualized rates of change in right prefrontal cortex thickness and third ventricle 
volume by anti-psychotic (AP) drug exposure during the inter-scan interval. Group 
differences were significant for both variables (F=7.46, p=0.000008 for right prefrontal 
cortex; F=3.74, p=0.005 for third ventricle). Converters with and without AP medications 
showed significantly steeper reduction in right prefrontal thickness and significantly greater 
expansion of the third ventricle compared with non-converters with and without AP 
medications and controls.
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Figure 3. 
Mean annualized rates of change in right prefrontal cortex thickness and third ventricle 
volume by duration of prodromal symptoms. Group differences were significant for both 
variables (F=9.68, p=0.0000002 for right prefrontal cortex; F=3.87, p=0.004 for third 
ventricle). Converters with short durations showed significantly steeper reduction in right 
prefrontal thickness compared with long-duration converters, short- and long-duration non-
converters, and controls; they also showed significantly greater third ventricle expansion 
compared with all of the groups except for long-duration converters. Converters with long 
durations showed significantly steeper reduction in right prefrontal thickness and 
significantly greater expansion of the third ventricle compared with long-duration non-
converters and controls.
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Table 1
Demographic Characteristics and Mean Rates of Change in Subcortical Regions by Group.
Characteristic Converters1 (N=35) Non-Converters (N=239) Controls2 (N=135) Statistic
Gender
 Male 25 (71%) 146 (61%) 73 (54%) χ2=3.9, p=0.13
 Female 10 (29%) 93 (39%) 62 (46%)
Race
 Caucasian 19 (54%) 134 (56%) 73 (54%) χ2=0.1, p=0.92
 Non-Caucasian 16 (46%) 105 (44%) 62 (46%)
Ethnicity
 Latino 6 (17%) 47 (20%) 20 (15%) χ2=1.4, p=0.49
 Non-Latino 29 (83%) 192 (80%) 115 (85%)
Substance Abuse Diagnosis 5 (14%) 24 (10%) 4 (3%) χ2=7.8, p=0.02
Antipsychotics3 22 (63%) 73 (30%) 0 (0%) χ2=78.8, p<.0001
Means and SDs
Age at Baseline 18.8 (3.8) 19.7 (4.2) 20.5 (4.6) F=2.7, p=0.06
Parental Education 6.7 (1.4) 6.2 (1.4) 6.8 (1.4) F=7.7, p=0.0005
Income 4.7 (1.9) 4.7 (1.9) 4.6 (1.8) F=0.1, p=0.89
Inter-scan Interval 0.9 (0.5) 1.0 (0.3) 1.1 (0.4) F=7.1, p=0.001
Positive Symptoms BL4 13.5 (3.1) 11.9 (4.1) 1.1 (1.7) F=479.6, p<.0001
Positive Symptoms FU4 18.3 (4.4) 7.8 (4.6) 0.7 (1.4) F=329.7, p<.0001
Antipsychotic dosage5 93.3 (133.7) 97.5 (122.3) N/A
Change in Brain Volumes6 FDR-Corrected P
 Left Thalamus −0.005 (0.06) 0.010 (0.06) 0.010 (0.04) 0.30
 Right Thalamus 0.011 (0.09) 0.004 (0.04) 0.005 (0.04) 0.69
 Left Caudate 0.015 (0.05) −0.003 (0.04) −0.004 (0.03) 0.20
 Right Caudate 0.010 (0.05) −0.004 (0.04) −0.004 (0.03) 0.21
 Left Putamen 0.014 (0.04) −0.001 (0.04) −0.001 (0.04) 0.20
 Right Putamen 0.006 (0.10) 0.005 (0.05) 0.001 (0.03) 0.69
 Left Pallidum 0.051 (0.19) 0.001 (0.12) 0.006 (0.11) 0.20
 Right Palldium 0.017 (0.10) 0.003 (0.06) −0.006 (0.09) 0.30
 Left Hippocampus −0.013 (0.06) 0.003 (0.04) −0.001 (0.04) 0.62
 Right Hippocampus −0.009 (0.04) 0.001 (0.03) −0.002 (0.03) 0.30
 Left Amygdala 0.022 (0.15) 0.016 (0.08) −0.009 (0.07) 0.20
 Right Amygdala 0.036 (0.13) 0.016 (0.09) −0.001 (0.08) 0.26
 Left Accumbens −0.032 (0.15) −0.019 (0.10) −0.008 (0.09) 0.63
 Right Accumbens −0.028 (0.16) −0.009 (0.09) −0.023 (0.07) 0.36
 Left Lateral Ventricle 0.064 (0.13) 0.024 (0.17) 0.011 (0.07) 0.31
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Characteristic Converters1 (N=35) Non-Converters (N=239) Controls2 (N=135) Statistic
 Right Lateral Ventricle 0.064 (0.15) 0.024 (0.16) 0.011 (0.07) 0.33
 Brain Stem 0.007 (0.04) 0.009 (0.03) 0.009 (0.02) 0.69
 Third Ventricle 0.086 (0.12) 0.015 (0.10) 0.011 (0.07) 0.01
 Fourth Ventricle 0.061 (0.14) 0.006 (0.12) 0.002 (0.06) 0.13
1A SIPS diagnosis of a psychotic syndrome refers to psychotic symptoms of particular intensity (eg, delusional conviction) and frequency or 
duration (≥ 1 h/d for ≥ 4 d/wk during the past month) or of particular impact (seriously disorganizing or dangerous), designed to operationalize the 
threshold for a DSM-IV psychotic disorder diagnosis. DSM-IV diagnoses of converters were as follows: schizophrenia (N=9), schizophreniform 
disorder (N=9), schizoaffective disorder, depressed type (N=2), bipolar disorder with psychotic features (N=3), psychosis not otherwise specified 
(N=12).
2
The only diagnostic exclusions for control subjects were psychotic disorders. A total of 17 (13%) of the controls had one or more DSM-IV 
diagnoses (8 with depression, 5 with anxiety disorders, 4 with substance use disorders, 2 with attention deficit disorder, 1 with somatization 
disorder, and 1 with oppositional-defiant disorder).
3
In addition to (second-generation) antipsychotics, 10 (29%) of the converters and 104 (44%) of the non-converters received anti-depressant 
medications during the inter-scan interval. Prescriptions for other types of medicine (stimulants, anticonvulsants, benzodiazapines) occurred 
infrequently (4 or fewer converters).
4
Positive symptoms reflect sum of the P1–P5 ratings on the Scale for the Assessment of Prodromal Symptoms.
5
In chlorpromazine equivalent units (65).
6
Mean (SD) annualized rates of change (negative values indicate shrinkage, positive values indicate expansion), with False-Discovery Rate (FDR) 
corrected p-values. Multiplying the values by 100 provides an index of annualized percentage change.
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Table 3
Correlations of annualized rates of change in right prefrontal cortex thickness and third ventricle volume with 
serum inflammatory indices by outcome group.
Region Group N Pro-inflammatory cytokines* Anti-inflammatory cytokines
Right PFC Control 35 0.12 −0.05
Non-Converter 38
−0.32¶ −0.02
Converter 14
−0.65§ 0.38
Overall 87
−0.37§ 0.06
3rd Ventricle Control 35 −0.18 −0.10
Non-Converter 38 0.09 0.06
Converter 14 −0.15 −0.41
Overall 87 −0.02 −0.10
§p<0.01;
¶p<0.05;
*
the relationship between pro-inflammatory cytokines and right PFC contraction was significantly greater in converters than in non-converters and 
controls (F=10.1, df=3,83, p=0.00001).
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